Brian Eastman

Brian Eastman is a seasoned scientist with extensive experience in drug discovery and development, particularly in small molecule inhibitors and biological pathways for oncology and regenerative medicine. Currently serving as Scientist III at Biosplice Therapeutics since November 2012, Brian has excelled in designing and synthesizing novel small molecule libraries and optimizing synthetic routes for analogs. Previous roles include significant contributions at Mpex Pharmaceuticals and SGX Pharmaceuticals, where Brian advanced lead series for specific pharmacological programs. Brian holds a Master's degree in Chemistry/Biochemistry from the University of Victoria, attained between 1993 to 1995, and has a robust publication history stemming from collaborative research efforts during tenures at various pharmaceutical companies, including Merck and Agouron Pharmaceuticals, where influential projects facilitated the development of the approved drug Rucaparib.